질 미생물군집 진단 시장 규모, 점유율 및 동향 분석 보고서 : 제품별, 기술별, 용도별, 최종 용도별, 지역별 및 부문별 전망(2026-2033년)

Vaginal Microbiome Diagnostics Market Summary

The global vaginal microbiome diagnostics market size was valued at USD 579.4 million in 2025 and is projected to grow from USD 659.6 million in 2026 to USD 1,727.3 million by 2033, at a CAGR of 14.7% from 2026 to 2033. North America dominated the market, accounting for the revenue share of 40.9% in 2025. Market growth is primarily driven by the high burden of bacterial vaginosis and vaginal dysbiosis, increasing adoption of molecular diagnostic technologies, and growing demand for accurate and comprehensive vaginal microbiome profiling.

Market Characteristics & Concentration

Regulations have a significant impact on the market by influencing product development, clinical validation, commercialization, and adoption across healthcare settings. In the U.S., nucleic acid detection systems intended to aid the diagnosis of vaginitis and bacterial vaginosis are regulated by the FDA as Class II in vitro diagnostic devices, requiring manufacturers to demonstrate appropriate analytical and clinical performance, along with applicable quality and labeling requirements.

Regulatory considerations become particularly important as companies expand from centralized laboratory testing toward decentralized molecular diagnostics, where usability and workflow performance must also be demonstrated.

Product expansion is strengthening the global market as companies broaden testing beyond pathogen identification to include the characterization of beneficial and dysbiosis-associated microorganisms. Newer solutions increasingly assess Lactobacillus species alongside organisms associated with bacterial vaginosis, candidiasis, mixed infections, and recurrent vaginal conditions, enabling a more comprehensive evaluation of vaginal microbial composition. Quantitative molecular methods and sequencing-based approaches can further expand the information obtained from a single specimen and support a more personalized interpretation of vaginal health.

For instance, in July 2026, CirrusDx launched LacP, a Lactobacillus panel designed to identify and quantify key Lactobacillus species the support a healthy vaginal environment. The expansion toward measuring protective microbial populations represents an important evolution beyond conventional pathogen-centered testing and can support the evaluation of dysbiosis and recurrent symptoms. Continued expansion of microbial targets, quantitative capabilities, and clinically interpreted results is expected to broaden the range of addressable applications for vaginal microbiome diagnostics.

Regional expansion is creating growth opportunities in the vaginal microbiome diagnostics industry as molecular testing, self-collection, digital healthcare, and specialized women's-health services increase access to vaginal microbiome assessment. North America benefits from an established molecular diagnostic infrastructure and reference laboratory networks, while Europe and the Asia Pacific offer expansion potential through improvements in molecular capabilities, reproductive health services, and the adoption of personalized diagnostics. Partnerships that connect microbiome testing with virtual clinical care can further increase access without requiring patients to follow exclusively conventional in-person diagnostic pathways. For instance, in June 2025, Organon and Evvy announced a U.S. collaboration integrating Evvy's vaginal microbiome testing and clinical-care platform with access to XACIATO for eligible patients diagnosed with bacterial vaginosis.

Global Vaginal Microbiome Diagnostics Market Report Segmentation

This report forecasts revenue growth at country levels and provides an analysis on the latest industry trends and opportunities in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global vaginal microbiome diagnostics market report based on the product, technology, application, end-use, and region:

• Product Outlook (Revenue, USD Million, 2021 - 2033)
• Instruments
• Reagents & Consumables
• Software & Services
• Technology Outlook (Revenue, USD Million, 2021 - 2033)
• PCR/qPCR & Other Targeted Nucleic Acid Amplification
• Next-Generation Sequencing
• Other Technologies
• Application Outlook (Revenue, USD Million, 2021 - 2033)
• Bacterial Vaginosis & Vaginal Dysbiosis
• Vulvovaginal Candidiasis
• Mixed & Recurrent Vaginitis
• Fertility, Pregnancy & Reproductive Health
• Menopause & Genitourinary Syndrome
• Other Applications
• End-use Outlook (Revenue, USD Million, 2021 - 2033)
• Hospitals & Clinics
• Diagnostic & Reference Laboratories
• Fertility & Reproductive Health Centers
• Direct-to-Consumer
• Other End-uses
• Regional Outlook (Revenue, USD Million; 2021 - 2033)
• North America

• U.S.
• Canada
• Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Norway
  • Denmark
  • Sweden
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Market Definitions
  • 1.2.1. Product Segment
  • 1.2.2. Technology Segment
  • 1.2.3. Application Segment
  • 1.2.4. End Use Segment
• 1.3. Information analysis
  • 1.3.1. Market formulation & data visualization
• 1.4. Data validation & publishing
• 1.5. Information Procurement
  • 1.5.1. Primary Research
• 1.6. Information or Data Analysis
• 1.7. Market Formulation & Validation
• 1.8. Market Model
• 1.9. Total Market: CAGR Calculation
• 1.10. Objectives
  • 1.10.1. Objective 1
  • 1.10.2. Objective 2

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Snapshot
• 2.3. Competitive Insights Landscape

Chapter 3. Global Vaginal Microbiome Diagnostics Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook.
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
  • 3.2.2. Market restraint analysis
  • 3.2.3. Market opportunity analysis
• 3.3. Global Vaginal Microbiome Diagnostics Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
  • 3.3.2. PESTEL Analysis

Chapter 4. Global Vaginal Microbiome Diagnostics Market: Product Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Global Vaginal Microbiome Diagnostics Market Product Movement Analysis
• 4.3. Global Vaginal Microbiome Diagnostics Market Size & Trend Analysis by Product, 2021 to 2033 (USD Million)
• 4.4. Instruments
  • 4.4.1. Instruments market estimates and forecasts 2021 to 2033 (USD Million)
• 4.5. Reagents & Consumables
  • 4.5.1. Reagents & Consumables market estimates and forecasts 2021 to 2033 (USD Million)
• 4.6. Software & Services
  • 4.6.1. Software & Services market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 5. Global Vaginal Microbiome Diagnostics Market: Technology Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Global Vaginal Microbiome Diagnostics Market Technology Movement Analysis
• 5.3. Global Vaginal Microbiome Diagnostics Market Size & Trend Analysis, by Technology, 2021 to 2033 (USD Million)
• 5.4. PCR/qPCR & Other Targeted Nucleic Acid Amplification
  • 5.4.1. PCR/qPCR & Other Targeted Nucleic Acid Amplification market estimates and forecasts 2021 to 2033 (USD Million)
• 5.5. Next-Generation Sequencing
  • 5.5.1. Next-Generation Sequencing market estimates and forecasts 2021 to 2033 (USD Million)
• 5.6. Other Technologies
  • 5.6.1. Other Technologies market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 6. Global Vaginal Microbiome Diagnostics Market: Application Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. Global Vaginal Microbiome Diagnostics Market Application Movement Analysis
  • 6.2.1. Global Vaginal Microbiome Diagnostics Market Size & Trend Analysis, by Application, 2021 to 2033 (USD Million)
• 6.3. Bacterial Vaginosis & Vaginal Dysbiosis
  • 6.3.1. Bacterial Vaginosis & Vaginal Dysbiosis market estimates and forecasts 2021 to 2033 (USD Million)
• 6.4. Vulvovaginal Candidiasis
  • 6.4.1. Vulvovaginal Candidiasis market estimates and forecasts 2021 to 2033 (USD Million)
• 6.5. Mixed & Recurrent Vaginitis
  • 6.5.1. Mixed & Recurrent Vaginitis market estimates and forecasts 2021 to 2033 (USD Million)
• 6.6. Fertility, Pregnancy & Reproductive Health
  • 6.6.1. Fertility, Pregnancy & Reproductive Health market estimates and forecasts 2021 to 2033 (USD Million)
• 6.7. Menopause & Genitourinary Syndrome
  • 6.7.1. Menopause & Genitourinary Syndrome market estimates and forecasts 2021 to 2033 (USD Million)
• 6.8. Other Applications
  • 6.8.1. Other Applications market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 7. Global Vaginal Microbiome Diagnostics Market: End Use Estimates & Trend Analysis

• 7.1. Segment Dashboard
• 7.2. Global Vaginal Microbiome Diagnostics Market End Use Movement Analysis
  • 7.2.1. Global Vaginal Microbiome Diagnostics Market Size & Trend Analysis, by End Use, 2021 to 2033 (USD Million)
• 7.3. Hospitals & Clinics
  • 7.3.1. Hospitals & Clinics market estimates and forecasts 2021 to 2033 (USD Million)
• 7.4. Diagnostic & Reference Laboratories
  • 7.4.1. Diagnostic & Reference Laboratories market estimates and forecasts 2021 to 2033 (USD Million)
• 7.5. Fertility & Reproductive Health Centers
  • 7.5.1. Fertility & Reproductive Health Centers market estimates and forecasts 2021 to 2033 (USD Million)
• 7.6. Direct-to-Consumer
  • 7.6.1. Direct-to-Consumer market estimates and forecasts 2021 to 2033 (USD Million)
• 7.7. Other End Users
  • 7.7.1. Other End Users market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 8. Vaginal Microbiome Diagnostics Market: Regional Estimates & Trend Analysis

• 8.1. Regional Dashboard
• 8.2. Market Size, & Forecasts Trend Analysis, 2021 to 2033:
• 8.3. North America
  • 8.3.1. U.S.
    • 8.3.1.1. Key country dynamics
    • 8.3.1.2. Regulatory framework/ reimbursement structure
    • 8.3.1.3. Competitive scenario
    • 8.3.1.4. U.S. market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.3.2. Canada
    • 8.3.2.1. Key country dynamics
    • 8.3.2.2. Regulatory framework/ reimbursement structure
    • 8.3.2.3. Competitive scenario
    • 8.3.2.4. Canada market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.3.3. Mexico
    • 8.3.3.1. Key country dynamics
    • 8.3.3.2. Regulatory framework/ reimbursement structure
    • 8.3.3.3. Competitive scenario
    • 8.3.3.4. Mexico market estimates and forecasts 2021 to 2033 (USD Million)
• 8.4. Europe
  • 8.4.1. UK
    • 8.4.1.1. Key country dynamics
    • 8.4.1.2. Regulatory framework/ reimbursement structure
    • 8.4.1.3. Competitive scenario
    • 8.4.1.4. UK market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.4.2. Germany
    • 8.4.2.1. Key country dynamics
    • 8.4.2.2. Regulatory framework/ reimbursement structure
    • 8.4.2.3. Competitive scenario
    • 8.4.2.4. Germany market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.4.3. France
    • 8.4.3.1. Key country dynamics
    • 8.4.3.2. Regulatory framework/ reimbursement structure
    • 8.4.3.3. Competitive scenario
    • 8.4.3.4. France market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.4.4. Italy
    • 8.4.4.1. Key country dynamics
    • 8.4.4.2. Regulatory framework/ reimbursement structure
    • 8.4.4.3. Competitive scenario
    • 8.4.4.4. Italy market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.4.5. Spain
    • 8.4.5.1. Key country dynamics
    • 8.4.5.2. Regulatory framework/ reimbursement structure
    • 8.4.5.3. Competitive scenario
    • 8.4.5.4. Spain market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.4.6. Norway
    • 8.4.6.1. Key country dynamics
    • 8.4.6.2. Regulatory framework/ reimbursement structure
    • 8.4.6.3. Competitive scenario
    • 8.4.6.4. Norway market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.4.7. Sweden
    • 8.4.7.1. Key country dynamics
    • 8.4.7.2. Regulatory framework/ reimbursement structure
    • 8.4.7.3. Competitive scenario
    • 8.4.7.4. Sweden market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.4.8. Denmark
    • 8.4.8.1. Key country dynamics
    • 8.4.8.2. Regulatory framework/ reimbursement structure
    • 8.4.8.3. Competitive scenario
    • 8.4.8.4. Denmark market estimates and forecasts 2021 to 2033 (USD Million)
• 8.5. Asia Pacific
  • 8.5.1. Japan
    • 8.5.1.1. Key country dynamics
    • 8.5.1.2. Regulatory framework/ reimbursement structure
    • 8.5.1.3. Competitive scenario
    • 8.5.1.4. Japan market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.5.2. China
    • 8.5.2.1. Key country dynamics
    • 8.5.2.2. Regulatory framework/ reimbursement structure
    • 8.5.2.3. Competitive scenario
    • 8.5.2.4. China market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.5.3. India
    • 8.5.3.1. Key country dynamics
    • 8.5.3.2. Regulatory framework/ reimbursement structure
    • 8.5.3.3. Competitive scenario
    • 8.5.3.4. India market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.5.4. Australia
    • 8.5.4.1. Key country dynamics
    • 8.5.4.2. Regulatory framework/ reimbursement structure
    • 8.5.4.3. Competitive scenario
    • 8.5.4.4. Australia market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.5.5. South Korea
    • 8.5.5.1. Key country dynamics
    • 8.5.5.2. Regulatory framework/ reimbursement structure
    • 8.5.5.3. Competitive scenario
    • 8.5.5.4. South Korea market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.5.6. Thailand
    • 8.5.6.1. Key country dynamics
    • 8.5.6.2. Regulatory framework/ reimbursement structure
    • 8.5.6.3. Competitive scenario
    • 8.5.6.4. Thailand market estimates and forecasts 2021 to 2033 (USD Million)
• 8.6. Latin America
  • 8.6.1. Brazil
    • 8.6.1.1. Key country dynamics
    • 8.6.1.2. Regulatory framework/ reimbursement structure
    • 8.6.1.3. Competitive scenario
    • 8.6.1.4. Brazil market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.6.2. Argentina
    • 8.6.2.1. Key country dynamics
    • 8.6.2.2. Regulatory framework/ reimbursement structure
    • 8.6.2.3. Competitive scenario
    • 8.6.2.4. Argentina market estimates and forecasts 2021 to 2033 (USD Million)
• 8.7. MEA
  • 8.7.1. South Africa
    • 8.7.1.1. Key country dynamics
    • 8.7.1.2. Regulatory framework/ reimbursement structure
    • 8.7.1.3. Competitive scenario
    • 8.7.1.4. South Africa market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.7.2. Saudi Arabia
    • 8.7.2.1. Key country dynamics
    • 8.7.2.2. Regulatory framework/ reimbursement structure
    • 8.7.2.3. Competitive scenario
    • 8.7.2.4. Saudi Arabia market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.7.3. UAE
    • 8.7.3.1. Key country dynamics
    • 8.7.3.2. Regulatory framework/ reimbursement structure
    • 8.7.3.3. Competitive scenario
    • 8.7.3.4. UAE market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.7.4. Kuwait
    • 8.7.4.1. Key country dynamics
    • 8.7.4.2. Regulatory framework/ reimbursement structure
    • 8.7.4.3. Competitive scenario
    • 8.7.4.4. Kuwait market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Company/Competition Categorization
• 9.2. Strategy Mapping
• 9.3. Company Market Share Analysis, 2025
• 9.4. List of Key Certification Providers/Scheme Owners
• 9.5. Company Profiles/Listing
  • 9.5.1. Hologic, Inc.
    • 9.5.1.1. Company overview
    • 9.5.1.2. Financial performance
    • 9.5.1.3. Product benchmarking
    • 9.5.1.4. Strategic initiatives
  • 9.5.2. Quest Diagnostics Incorporated
    • 9.5.2.1. Company overview
    • 9.5.2.2. Financial performance
    • 9.5.2.3. Product benchmarking
    • 9.5.2.4. Strategic initiatives
  • 9.5.3. Labcorp Holdings Inc.
    • 9.5.3.1. Company overview
    • 9.5.3.2. Financial performance
    • 9.5.3.3. Product benchmarking
    • 9.5.3.4. Strategic initiatives
  • 9.5.4. Cepheid / Danaher Corporation
    • 9.5.4.1. Company overview
    • 9.5.4.2. Financial performance
    • 9.5.4.3. Product benchmarking
    • 9.5.4.4. Strategic initiatives
  • 9.5.5. Becton, Dickinson and Company
    • 9.5.5.1. Company overview
    • 9.5.5.2. Financial performance
    • 9.5.5.3. Product benchmarking
    • 9.5.5.4. Strategic initiatives
  • 9.5.6. Seegene, Inc.
    • 9.5.6.1. Company overview
    • 9.5.6.2. Financial performance
    • 9.5.6.3. Product benchmarking
    • 9.5.6.4. Strategic initiatives
  • 9.5.7. Mayo Clinic Laboratories
    • 9.5.7.1. Company overview
    • 9.5.7.2. Financial performance
    • 9.5.7.3. Product benchmarking
    • 9.5.7.4. Strategic initiatives
  • 9.5.8. F. Hoffmann-La Roche Ltd.
    • 9.5.8.1. Company overview
    • 9.5.8.2. Financial performance
    • 9.5.8.3. Product benchmarking
    • 9.5.8.4. Strategic initiatives
  • 9.5.9. Evvy
    • 9.5.9.1. Company overview
    • 9.5.9.2. Financial performance
    • 9.5.9.3. Product benchmarking
    • 9.5.9.4. Strategic initiatives
  • 9.5.10. Juno Bio
    • 9.5.10.1. Company overview
    • 9.5.10.2. Financial performance
    • 9.5.10.3. Product benchmarking
    • 9.5.10.4. Strategic initiatives